Single User License
INR 100350
Site License
INR 200700
Corporate User License
INR 301050

Service Tax Additional

select a format

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

AbbVie Inc.-Product Pipeline Review-2015

AbbVie Inc.-Product Pipeline Review-2015

  Request for Sample Report

Executive Summary

AbbVie Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'AbbVie Inc.-Product Pipeline Review-2015', provides an overview of the AbbVie Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AbbVie Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of AbbVie Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of AbbVie Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the AbbVie Inc.'s pipeline products

Reasons To Buy

Evaluate AbbVie Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of AbbVie Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the AbbVie Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of AbbVie Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of AbbVie Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of AbbVie Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

AbbVie Inc. Snapshot 6

AbbVie Inc. Overview 6

Key Information 6

Key Facts 6

AbbVie Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

AbbVie Inc.-Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products-Monotherapy 14

Pipeline Products-Combination Treatment Modalities 15

Pipeline Products-Partnered Products 16

Pipeline Products-Out-Licensed Products 18

AbbVie Inc.-Pipeline Products Glance 20

AbbVie Inc.-Late Stage Pipeline Products 20

AbbVie Inc.-Clinical Stage Pipeline Products 23

AbbVie Inc.-Early Stage Pipeline Products 25

AbbVie Inc.-Drug Profiles 28

(ombitasvir + paritaprevir + ritonavir) 28

adalimumab 30

daclizumab 32

(carbidopa + levodopa) 35

atrasentan hydrochloride 36

elagolix sodium 37

elotuzumab 38

fluvoxamine maleate 40

ombitasvir 41

paricalcitol 42

paritaprevir 43

veliparib 45

venetoclax 48

ABT-122 51

ABT-414 52

ABT-436 54

ABT-493 55

ABT-493 + ABT-530 56

ABT-494 57

ABT-530 58

ABT-806 59

ABT-981 60

navitoclax dihydrochloride 61

ABBV-075 63

ABBV-084 64

ABBV-221 65

ABBV-399 66

ABBV-672 67

ABT-165 68

ABT-257 69

ABT-354 70

ABT-700 71

ABT-767 72

ABT-957 73

Antibody Drug Conjugate to Inhibit EFGR for Squamous Cell Tumor and Glioblastoma 74

ilorasertib 75

A-1048400 77

A-1264087 78

A-431404 79

A-705253 80

A-801195 81

A-889425 82

A-918446 83

ABT-487 84

ABT-731 85

ABT-737 86

ABT-898 88

Antisense Gene Therapy to Inhibit Aldehyde Dehydrogenase for Alcoholism 89

APG-880 90

Monoclonal Antibodies to Inhibit Tau for Alzheimer's Disease and Tauopathies 91

Monoclonal Antibody Conjugates for Cancer 92

SLV-330 93

Small Molecule to Inhibit PKC Theta for Autoimmune Disease 94

Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology 95

SOL-1 96

Monoclonal Antibodies for Chronic Pain 97

Small Molecules to Inhibit CDPK1 for Protozoal Infections 98

Small Molecules to Inhibit MCL-1 for Cancer 99

AbbVie Inc.-Pipeline Analysis 100

AbbVie Inc.-Pipeline Products by Target 100

AbbVie Inc.-Pipeline Products by Route of Administration 104

AbbVie Inc.-Pipeline Products by Molecule Type 105

AbbVie Inc.-Pipeline Products by Mechanism of Action 106

AbbVie Inc.-Recent Pipeline Updates 109

AbbVie Inc.-Dormant Projects 129

AbbVie Inc.-Discontinued Pipeline Products 133

Discontinued Pipeline Product Profiles 133

AbbVie Inc.-Company Statement 138

AbbVie Inc.-Locations And Subsidiaries 141

Head Office 141

Other Locations & Subsidiaries 141

Appendix 149

Methodology 149

Coverage 149

Secondary Research 149

Primary Research 149

Expert Panel Validation 149

Contact Us 149

Disclaimer 150

List of Tables

AbbVie Inc., Key Information 10

AbbVie Inc., Key Facts 10

AbbVie Inc.-Pipeline by Indication, 2015 12

AbbVie Inc.-Pipeline by Stage of Development, 2015 17

AbbVie Inc.-Monotherapy Products in Pipeline, 2015 18

AbbVie Inc.-Combination Treatment Modalities in Pipeline, 2015 19

AbbVie Inc.-Partnered Products in Pipeline, 2015 20

AbbVie Inc.-Partnered Products/ Combination Treatment Modalities, 2015 21

AbbVie Inc.-Out-Licensed Products in Pipeline, 2015 22

AbbVie Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 23

AbbVie Inc.-Pre-Registration, 2015 24

AbbVie Inc.-Filing rejected/Withdrawn, 2015 25

AbbVie Inc.-Phase III, 2015 26

AbbVie Inc.-Phase II, 2015 27

AbbVie Inc.-Phase I, 2015 28

AbbVie Inc.-Preclinical, 2015 29

AbbVie Inc.-Discovery, 2015 31

AbbVie Inc.-Pipeline by Target, 2015 105

AbbVie Inc.-Pipeline by Route of Administration, 2015 108

AbbVie Inc.-Pipeline by Molecule Type, 2015 109

AbbVie Inc.-Pipeline Products by Mechanism of Action, 2015 110

AbbVie Inc.-Recent Pipeline Updates, 2015 113

AbbVie Inc.-Dormant Developmental Projects,2015 133

AbbVie Inc.-Discontinued Pipeline Products, 2015 137

AbbVie Inc., Subsidiaries 145

List of Figures

AbbVie Inc.-Pipeline by Top 10 Indication, 2015 12

AbbVie Inc.-Pipeline by Stage of Development, 2015 17

AbbVie Inc.-Monotherapy Products in Pipeline, 2015 18

AbbVie Inc.-Combination Treatment Modalities in Pipeline, 2015 19

AbbVie Inc.-Partnered Products in Pipeline, 2015 20

AbbVie Inc.-Out-Licensed Products in Pipeline, 2015 22

AbbVie Inc.-Pipeline by Top 10 Target, 2015 104

AbbVie Inc.-Pipeline by Top 10 Route of Administration, 2015 108

AbbVie Inc.-Pipeline by Top 10 Molecule Type, 2015 109

AbbVie Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 110

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of AbbVie Inc.; AbbVie Inc. - Key Therapeutics; AbbVie Inc. - Pipeline Overview and Promising Molecules; AbbVie Inc. - News; AbbVie Inc. - Latest Updates; AbbVie Inc. - Pipeline; AbbVie Inc. - Discontinued/Dormant Projects

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]